Recently, Gut published a review of guidelines for the management of gastric intestinal metaplasia (GIM) with the goal of promoting harmonisation of the guidelines regarding indications for endoscopic screening for gastric cancer and GIM detection/staging, metrics for high-quality endoscopy and non-endoscopic interventions for gastric cancer prevention in patients with GIM.1 GIM is not a disease per se but rather is a reparative response to gastric mucosal injury that may be present, at least temporarily, as part of healing such as of an ulcer.2 Clinically, widespread GIM is best considered a manifestation of healing of another disease, typically Helicobacter pylori infection or autoimmune gastritis. When present in autoimmune gastritis, GIM has no malignant potential and is potentially completely reversible.3 In contrast, when associated with chronic H. pylori infection, GIM is typically permanent and, at most, minimally reversible.4 The underlying H. pylori-induced inflammation…
Search Results for: Trattamento dell'infezione da Helicobacter Pylori
Here's what we've found for you
Correction for 'Protocol for a randomised 'screen-andtreat Helicobacter pylori eradication trial in 14-18-years-old adolescents residing in three regions of Chile: effectiveness and microbiological host implications
George S, Lucero Y, Cabrera C, et al. Protocol for a randomised ‘screen-and-treat’ Helicobacter pylori eradication trial in 14–18-years-old adolescents residing in three regions of Chile: effectiveness and microbiological host implications. BMJ Open 2025;15:e084984. doi:10.1136/bmjopen-2024–0 84 984
This article has been corrected since it was published online. The funding information has been updated from “The funder has no influence on the study’s design, execution, analysis, or publication of results. The funder has no influence on the study’s design, execution, analysis, or publication of results. The funder has no influence on the study’s design, execution, analysis, or publication of results.” to “This trial has received funding from the National Fund for Scientific and Technological Development (Fondecyt 1 220 964 and 1190456). MO received partial funding from the grant ANID PIA AFB 230002. The funder has no influence on the study’s design, execution, analysis, or publication of results.”
La crioablazione nuova frontiera nella cura del tumore al seno
Trattamento rapido e tollerato con ridotto impatto estetico
La crioablazione nuova frontiera nella cura del tumore al seno
Trattamento rapido e tollerato con ridotto impatto estetico
Ha ustioni nell'80% del corpo, trattamento le rigenera la cute
Nel 2019 il marito tentò di ucciderla dandole fuoco
Linee guida sul trattamento dell’emicrania episodica acuta
Le nuove linee guida sul trattamento dell’emicrania episodica acuta forniscono […]
Diagnosi e gestione delle condizioni premaligne gastriche
L’American College of Gastroenterology ha pubblicato le linee guida per […]
Aziende di farmaci generici contro una direttiva Ue, 'causa rincari'
Obbliga le aziende a contribuire a costi di trattamento delle acque
Tumore alla prostata, una nuova cura blocca le metastasi
I risultati di uno studio (RADIOSA) dell’Istituto Europeo di Oncologia, […]
Screening for Helicobacter pylori to Prevent Gastric Cancer
To the Editor A recent study shed light on the potential value of FIT combined with HPSA testing in gastric cancer screening, while also indirectly highlighting the potential link between H pylori infection and colorectal carcinogenesis. We would like to discuss aspects of the study that require careful interpretation and further exploration.
Screening for Helicobacter pylori to Prevent Gastric Cancer—Reply
In Reply In response to the Letters regarding our recent article, we agree with Dr Shiratori and colleagues that our study requires a longer follow-up period, as was also noted by Drs Kumar and Bretthauer and by Dr Liu and colleagues. In our pragmatic trial, factors such as nonadherence to invitation, difference in participant characteristics, and limited treatment uptake have attenuated the potential benefits observed in earlier trials. To address this, we have provided the cumulative curve as requested and included a future projection based on the observed trends (Figure). In our trial, a nonsignificant 14% risk reduction was observed in 2020. However, with an extended follow-up to 2023, a significant 21% reduction would be expected after projection.
Screening for Helicobacter pylori to Prevent Gastric Cancer
To the Editor A recent randomized trial involving residents of Changhua County, Taiwan, offered valuable insights into the effectiveness of HPSA testing combined with FIT for colorectal cancer screening. While the study provides robust data, several key findings warrant further reflection.
Screening for Helicobacter pylori to Prevent Gastric Cancer
To the Editor Dr Lee and colleagues conducted a randomized, population-based trial in Taiwan to assess whether the addition of the Helicobacter pylori stool antigen (HPSA) test to the standard fecal immunochemical test (FIT) could reduce gastric cancer incidence and mortality. The study reported no significant differences between the 2 groups in gastric cancer incidence (0.032% vs 0.037%; P = .23) or mortality (0.015% vs 0.013%; P = .57). Several points merit further discussion.
Screening for Helicobacter pylori to Prevent Gastric Cancer
To the Editor In a recent trial, there were no differences in gastric cancer incidence or mortality between the 2 treatment groups at a median follow-up of 5.7 years (IQR, 4.9-6.5 years). The progression time from early asymptomatic to symptomatic gastric cancer is unknown and may be longer than the follow-up time of the trial. Presentation of cumulative incidence curves would be helpful to further gauge the effect of the intervention. Furthermore, the study excluded 4 patients with gastric cancer diagnosed on endoscopy after trial entry. While H pylori eradication may not have affected the development of cancer in these patients, excluding them creates bias because the control group was not exposed to gastroscopy with early detection of prevalent cancers. We suggest a recalculation of screening effects including the 4 patients who were excluded. Additionally, we are interested to know if more than 1 H pylori stool test was offered (for example, with subsequent FIT), which would provide information about reinfection and subsequent cancer risk.
Dopo il broncospasmo si può rischiare nuova polmonite
La pneumologa Dagmar Rinnenburger: “L’aspirazione per evitare infezione da ingestione”
Cancro al seno avanzato: diagnosi e trattamento
Questa linea guida pubblicata da NICE, riguarda l’assistenza e il supporto per […]